Aptamer 学术简报 — therapeutic — 2026-09-30

自动生成 by RBTX Aptamer Tracker v0.1。 子主题 therapeutic：近 14 天 54 篇命中（aptamer 池 173 篇）。

评分公式：composite = 0.45×log(IF) + 0.35×log(cites_velocity) + 0.10×social + 0.10×recency_bonus；满分 100。

#1 [14.3] Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma.

Therapeutic strategies for glioblastoma have progressed considerably over recent decades. Despite the development of new biomedical technologies and advances in our understanding of physiology and disease progression, effective drug delivery to brain cancer remains a significant challenge. The challenge is delivering therapeutics to the correct ...

#2 [14.3] Continuous Molecular Monitoring Using Electrochemical Aptamer-Based Sensors: Remaining Challenges for Long-Term In Vivo Deployment.

In vivo continuous molecular monitoring represents a long-standing, transformative objective in medicine, with the potential to fundamentally reshape disease diagnostics, therapeutic decision-making, and long-term patient management by providing dynamic biochemical information that is currently inaccessible. Electrochemical aptamer-based biosens...

#3 [14.2] A Self-Propelled DNA-Based Nanorobot for Hypoxic Tumor Therapy.

Solid tumors pose major therapeutic hurdles due to pathophysiological barriers such as hypoxia and dense stroma, which severely restrict drug penetration. Conventional nanomedicines lack the autonomous capability to navigate these evolving obstacles. Here, we engineer a DNA‑based nanorobot constructed on an optimized tetrahedral framework nuclei...

#4 [13.7] Detaching Photosensitive Nanoparticles from Cells Prevents Them from Remaining in Cells after Photoporation

ABSTRACT Efficient and safe intracellular delivery of macromolecules, like nucleic acids, remains a major challenge in ex vivo cell engineering. While photoporation is a highly attractive method for cytosolic delivery of (macro)molecules, photosensitizers remaining in the photoporated cells may pose safety concerns, especially when the cells are...

#5 [13.2] DNA Nanoassembly Modified Polydopamine@MnO(2) Nanoparticles: Enhancement of miRNA-21 Downregulation for Reversal of Breast Cancer Drug-Resistance.

Downregulating oncogenic microRNAs (miRNAs) is an attractive strategy for reversing drug resistance in cancer therapy. Compared to antisense, DNAzyme (Dz) possesses advantages such as recyclability and stability. However, it still suffers from insufficient stability and inadequate endogenous cofactors. Herein, by using miRNA-21 (miR-21) as targe...

#6 [12.8] Inhalable mucus-penetrating and senescence-targeted nanoliposomes reverse senescence to overcome chemoresistance for enhanced lung cancer therapy.

Lung cancer therapy is severely hindered by the pulmonary mucus barrier and chemotherapy resistance driven by therapy-induced senescence (TIS) following DNA-damaging agents. Herein, we report an inhalable, mucus-penetrating nanoliposomes (DR@DPPC-Apt) engineered by incorporating an L1 cell adhesion molecule (L1CAM)-targeting cholesterol-modified...

#7 [12.6] Membrane-Coated DNA Nanoflowers Attenuate Cognitive Decline in Apolipoprotein E4 Mice.

APOE4-driven mitochondrial dysfunction is one of the important primary drivers of cognitive decline in neurodegenerative diseases. However, achieving mitochondrial-targeted drug delivery in the nervous system requires overcoming multiple barriers, necessitating the development of a safer and more efficient bionanoparticle drug delivery system. D...

#8 [11.9] Myelin-Inspired 3D PEGylation of Framework Nucleic Acids Enables Simultaneous Long Circulation and Rapid Renal Clearance.

The rational design of nanomedicines is fundamentally constrained by a physicochemical paradox at the bio-nano interface: strategies to prolong circulation inevitably suppress clearance, often resulting in long-term accumulation and systemic toxicity. To address this, we propose spatial conformation engineering as an additional design dimension ...

#9 [11.9] Modular Lysosome-Targeting Platform Based on a Multivalent DNA Framework for Programmable Protein Degradation.

Targeted degradation of extracellular and membrane-bound proteins holds immense therapeutic potential but remains technically challenging. Lysosome-targeting chimeras (LYTACs) have emerged to bridge this gap, yet platforms built on monomeric aptamers suffer from inadequate stability, inefficient cellular uptake, and a lack of modularity. Here, w...

#10 [11.3] Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

Acute Myeloid Leukemia (AML) is a prevalent and aggressive hematologic cancer driven by leukemic stem cells and immune evasion. Among its subtypes, Mixed Lineage Leukemia-AF9 (MLL-AF9)- rearranged AML is exceptionally lethal, with B-cell lymphoma 2 (Bcl2), a key anti-apoptotic protein, supporting leukemic survival and immune dysfunction. Targeti...

Methodology